Expertise in

conditions

Dr. John M. Schallenkamp

Radiation Oncology

Sheridan Memorial Hospital

1401 W 5th St,

Sheridan, WY

Accepting New Patients

Offers Telehealth

Expertise in

conditions

Sheridan Memorial Hospital

1401 W 5th St,

Sheridan, WY

Overview

John Schallenkamp is a Radiation Oncologist practicing medicine in Sheridan, Wyoming.

Dr. Schallenkamp is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Astrocytoma, Familial Prostate Cancer, Prostatectomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 145 clinical trials. Dr. Schallenkamp is currently accepting new patients.

Graduate Institution

Medical College Of Wisconsin

Specialties

Radiation Oncology

Licenses

Radiology in MT

Hospital Affiliations

Poudre Valley Hospital

Platte County Hospital

Billings Clinic Hospital

Sheridan Memorial Hospital

Cheyenne Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Blue Cross Blue Shield

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Humana

HMO
INDEMNITY
POS
PPO

Medicaid

OTHER MEDICAID
STATE MEDICAID

Mountain Health

OTHER COMMERCIAL
POS
PPO

Northern Plains Alliance

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE PDP

PacificSource

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 5 Less Insurance Carriers -

Locations

Sheridan Memorial Hospital
1401 W 5th St, Sheridan, WY 82801

Call: 406-238-2500

Other Locations

Billings Clinic
801 N 29th St, Billings, MT 59101

Call: 406-238-2500

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

145 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2026

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium

Study Phase: Phase 3

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2026

Intervention Type: Other, Procedure, Drug, Biological

Study Phase: Phase 3

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Enrollment Status: Active_not_recruiting

Publish Date: September 04, 2026

Intervention Type: Other, Procedure

Study Phase: Phase 3

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Enrollment Status: Suspended

Publish Date: September 04, 2026

Intervention Type: Procedure, Radiation, Drug

Study Drug: Atezolizumab

Study Phase: Phase 2/Phase 3

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

Enrollment Status: Terminated

Publish Date: September 04, 2026

Intervention Type: Other, Drug

Study Drug: Aspirin

Study Phase: Phase 3

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 02, 2026

Intervention Type: Other

Study Phase: Phase 3

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Enrollment Status: Suspended

Publish Date: September 01, 2026

Intervention Type: Procedure, Drug, Other, Radiation, Biological

Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel

Study Phase: Phase 2/Phase 3

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: August 31, 2026

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma

Enrollment Status: Active_not_recruiting

Publish Date: August 31, 2026

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: August 31, 2026

Intervention Type: Radiation, Procedure

Study Phase: Phase 3

View 9 Less Clinical Trials

5 Total Publications

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 26, 2024

View All 5 Publications

Frequently Asked Questions about Dr. John M. Schallenkamp

How do I make an appointment with Dr. John M. Schallenkamp?

You can book an appointment with Dr. John M. Schallenkamp by calling their office at 406-238-2500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John M. Schallenkamp a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John M. Schallenkamp is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John M. Schallenkamp specialize in?

While Dr. John M. Schallenkamp is a Radiation Oncology, they have specific expertise in Lung Cancer, Astrocytoma, and Familial Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. John M. Schallenkamp participate in research or clinical trials?

Yes. Dr. John M. Schallenkamp has published 5 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. John M. Schallenkamp's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John M. Schallenkamp accept my insurance?

Dr. John M. Schallenkamp accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 406-238-2500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schallenkamp's expertise for a condition

ConditionClose